New Faces at Pfizer VC, BD Outfits
This article was originally published in Start Up
Pfizer Inc., as part of its reorganization, brought aboard veteran VC Barbara Dalton and former Pfizer executive, Tony Scullion, to head its venture capital and business development groups, respectively.
You may also be interested in...
Inverness Medical Innovations and Beckman Coulter are currently in a bidding war for Biosite and its point of care BNP test. The fight is just one example of the demand for innovative diagnostic test content. The recent upswing in IVD deal-making, along with renewed VC interest in diagnostics, suggests that the area's potential to drive health care innovation by directing therapy more efficiently is finally being recognized.
Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.
The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.